ASCENDIS PHARMA A/S - ADR (ASND) Stock Analyst Earnings Estimates
NASDAQ:ASND - Nasdaq - US04351P1012 - ADR - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 51.17M 557.71% | 266.718M 421.24% | 363.641M 36.34% | 568.6M 56.36% | 1.033B 81.67% | 1.606B 55.47% | 2.041B 27.09% | 2.598B 27.29% | 3.092B 19.01% | 3.039B -1.71% | 3.295B 8.42% | |
| EBITDA YoY % growth | -543.86M -24.63% | -428.796M 21.16% | -261.049M 39.12% | -185.666M 28.88% | 197.04M 206.13% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -561.81M -24.35% | -447.707M 20.31% | -278.763M 37.74% | -213.578M 23.38% | 168.02M 178.67% | 459.15M 173.27% | 966.79M 110.56% | 1.34B 38.60% | 1.717B 28.13% | 1.375B -19.92% | 1.528B 11.13% | |
| Operating Margin | -1,097.93% | -167.86% | -76.66% | -37.56% | 16.27% | 28.59% | 47.37% | 51.58% | 55.53% | 45.25% | 46.37% | |
| EPS YoY % growth | -10.40 -48.36% | -8.56 17.69% | -6.57 23.25% | -3.88 40.97% | 1.15 129.60% | 6.32 450.32% | 13.43 112.53% | 17.48 30.18% | 22.08 26.34% | 21.04 -4.71% | 23.86 13.40% |
All data in EUR
| Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -1.39 39.38% | -1.13 40.72% | -0.68 60.74% | -0.38 41.32% | 1.72 223.19% | 1.71 250.72% | 1.71 352.87% | 1.70 551.95% |
| Revenue Q2Q % growth | 97.12M 1.28% | 129.31M 259.21% | 161.16M 178.66% | 193.57M 11.30% | 305.66M 214.72% | 307.15M 137.53% | 309.19M 91.85% | 310.73M 60.53% |
| EBITDA Q2Q % growth | -89.974M -101.43% | -62.526M 49.73% | -39.892M 52.23% | -24.827M -237.19% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -82.161M -67.18% | -62.6M 53.02% | -38.292M 60.42% | -17.195M -4,589.57% | N/A | N/A | N/A | N/A |
All data in EUR
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q4 2024 Q2Q % growth | -0.64 58.44% | -0.98 | 0.34 | 34.50% |
| Q3 2024 Q2Q % growth | -1.72 40.28% | -1.77 | 0.05 | 3.09% |
| Q2 2024 Q2Q % growth | -1.91 11.57% | -1.41 | -0.50 | -35.43% |
| Q1 2024 Q2Q % growth | -2.30 -16.16% | -1.53 | -0.77 | -50.09% |
| Q4 2023 Q2Q % growth | -1.54 58.38% | -2.07 | 0.53 | 25.51% |
| Q3 2023 Q2Q % growth | -2.88 4.95% | -2.43 | -0.45 | -18.71% |
| Q2 2023 Q2Q % growth | -2.16 -47.95% | -2.64 | 0.48 | 18.26% |
| Q1 2023 Q2Q % growth | -1.98 10.41% | -2.71 | 0.73 | 27.04% |
| Q4 2022 Q2Q % growth | -3.70 -97.86% | -2.61 | -1.09 | -41.66% |
| Q3 2022 Q2Q % growth | -3.03 -106.12% | -2.54 | -0.49 | -19.31% |
| Q2 2022 Q2Q % growth | -1.46 41.60% | -2.17 | 0.71 | 32.87% |
| Q1 2022 Q2Q % growth | -2.21 -88.89% | -2.04 | -0.17 | -8.34% |
| Q4 2021 Q2Q % growth | -1.87 29.17% | -2.39 | 0.52 | 21.73% |
| Q3 2021 Q2Q % growth | -1.47 36.36% | -2.34 | 0.87 | 37.16% |
| Q2 2021 Q2Q % growth | -2.50 -26.90% | -2.27 | -0.23 | -10.14% |
| Q1 2021 Q2Q % growth | -1.17 11.36% | -1.74 | 0.57 | 32.73% |
| Q4 2020 Q2Q % growth | -2.64 -55.29% | -1.58 | -1.06 | -66.91% |
| Q3 2020 Q2Q % growth | -2.31 -335.85% | -1.61 | -0.70 | -43.80% |
| Q2 2020 Q2Q % growth | -1.97 -57.60% | -1.48 | -0.49 | -32.97% |
| Q1 2020 Q2Q % growth | -1.32 -6.45% | -1.38 | 0.06 | 4.01% |
| Q4 2019 Q2Q % growth | -1.70 | -1.49 | -0.21 | -14.18% |
| Q3 2019 Q2Q % growth | -0.53 | -1.21 | 0.68 | 56.30% |
| Q2 2019 Q2Q % growth | -1.25 | -1.23 | -0.02 | -1.41% |
| Q1 2019 Q2Q % growth | -1.24 | -1.02 | -0.22 | -21.37% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q4 2024 Q2Q % growth | 173.916M 26.30% | 122.1M | 51.816M | 42.44% |
| Q3 2024 Q2Q % growth | 57.833M 20.40% | 84.011M | -26.178M | -31.16% |
| Q2 2024 Q2Q % growth | 35.998M -24.04% | 85.651M | -49.653M | -57.97% |
| Q1 2024 Q2Q % growth | 95.894M 185.49% | 81.081M | 14.813M | 18.27% |
| Q4 2023 Q2Q % growth | 137.703M 501.32% | 64.385M | 73.318M | 113.87% |
| Q3 2023 Q2Q % growth | 48.034M 214.15% | 49.077M | -1.043M | -2.13% |
| Q2 2023 Q2Q % growth | 47.393M 669.37% | 38.097M | 9.296M | 24.40% |
| Q1 2023 Q2Q % growth | 33.589M 391.79% | 21.956M | 11.633M | 52.98% |
| Q4 2022 Q2Q % growth | 22.9M 367.35% | 20.233M | 2.667M | 13.18% |
| Q3 2022 Q2Q % growth | 15.29M 1,277.48% | 9.062M | 6.228M | 68.73% |
| Q2 2022 Q2Q % growth | 6.16M 503.92% | 5.927M | 233K | 3.93% |
| Q1 2022 Q2Q % growth | 6.83M 810.67% | 4.766M | 2.064M | 43.31% |
| Q4 2021 Q2Q % growth | 4.9M 807.41% | 2.712M | 2.188M | 80.68% |
| Q3 2021 Q2Q % growth | 1.11M -59.78% | 1.16M | -50K | -4.31% |
| Q2 2021 Q2Q % growth | 1.02M -29.17% | 862.41K | 157.59K | 18.27% |
| Q1 2021 Q2Q % growth | 750K -66.37% | 1.917M | -1.167M | -60.88% |
| Q4 2020 Q2Q % growth | 540K -78.49% | 1.709M | -1.169M | -68.40% |
| Q3 2020 Q2Q % growth | 2.76M 23.21% | 1.426M | 1.334M | 93.55% |
| Q2 2020 Q2Q % growth | 1.44M -55.14% | 2.23M | -790K | -35.43% |
| Q1 2020 Q2Q % growth | 2.23M -58.78% | 1.89M | 340K | 17.99% |
| Q4 2019 Q2Q % growth | 2.51M | 1.372M | 1.138M | 82.94% |
| Q3 2019 Q2Q % growth | 2.24M | 809.37K | 1.431M | 176.76% |
| Q2 2019 Q2Q % growth | 3.21M | 258.397K | 2.952M | 1,142.28% |
| Q1 2019 Q2Q % growth | 5.41M | 377.4K | 5.033M | 1,333.49% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 3.64% | -469.58% | 9.12% | -0.31% |
| Revenue | 7.53% | -43.7% | 6.54% | 1.72% |